Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06445114 · ClinicalTrials.gov registry record · Phase 2

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

A Phase 2 study of Carcinoma and Oropharyngeal Cancer, sponsored by Zachary Zumsteg.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
4
Study locations

NCT06445114: Recruiting Phase 2 study of Carcinoma and Oropharyngeal Cancer, sponsored by Zachary Zumsteg.

NCT06445114 is a Phase 2 study of Carcinoma and Oropharyngeal Cancer that is actively recruiting participants, run by Zachary Zumsteg. The registered enrollment target is 50 participants, below the 253-participant average among 29 other Carcinoma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06445114, a Phase 2 study of Carcinoma and Oropharyngeal Cancer, is actively recruiting participants, sponsored by Zachary Zumsteg.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
4
Study locations

Study Summary

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.

Primary Outcome

The primary objective of this study is to assess the 2-year progression-free survival (PFS) of de-intensified post-operative chemoradiation in patients with HPV-associated oropharyngeal cancer when basing treatment intensity on both standard pathologic features and post-operative Blood-based circulating tumor tissue modified viral (cTTMV-HPV DNA)

Interventions

  • DRUG Cisplatin

Study Locations (4)

California

  • Cedars-Sinai Cancer at Beverly Hills (THO) - Beverly Hills
  • Cedars Sinai Medical Center - Los Angeles
  • CS Cancer at Valley Oncology Medical Group - Tarzana
  • CS Cancer at the Hunt Cancer Center - Torrance

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-05-12
Est. Completion 2032-06
Phase Phase 2
Zachary Zumsteg

1 total trials

What NCT06445114 shows while recruiting

NCT06445114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 253-participant average among 29 other Carcinoma trials with a reported enrollment target (80% lower).

The record links to 2 conditions, with Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin is the first listed.

NCT06445114 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06445114 about?

NCT06445114 is a clinical study titled "Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer". This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.

What is the current status of trial NCT06445114?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-05-12. Estimated completion is 2032-06.

What conditions does trial NCT06445114 study?

This clinical trial studies the following conditions: Carcinoma, Oropharyngeal Cancer.

What interventions are being tested in trial NCT06445114?

The interventions under investigation include: Cisplatin (DRUG).

Who is sponsoring clinical trial NCT06445114?

This trial is sponsored by Zachary Zumsteg, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06445114 being conducted?

This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06445114's enrollment target sits among peer trials

50 21st of 29 higher than 9 of 29 other Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06445114, the US trial registry maintained by the National Library of Medicine. NCT06445114 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.